Please login to the form below

Not currently logged in
Email:
Password:
PMLiVE Top Pharma List

20

Revenue 2017

Triumeq

The Top Pharma List's top 50 pharmaceutical products by global sales ranking is compiled from GlobalData's pharmaceutical revenue figures. Triumeq was produced by GlaxoSmithKline.

Germany gives green light to Viiv's Triumeq for HIV

Germany gives green light to Viiv's Triumeq for HIV Triumeq combines ViiV's antiretroviral stalwarts lamivudine and abacavir with its new integrase inhibitor Tivicay (dolutegravir), which was backed by IQWIG last year. ... month. Treatment-naïve patients make up the largest target population for Triumeq,

Cancer drugs lead SMC recommendations

Cancer drugs lead SMC recommendations Triumeq is a combination of dolutegravir, abacavir and lamivudine developed by ViiV Healthcare, a partnership between Pfizer, GSK and Shionogi.

GSK to sell off part of its HIV venture ViiV Healthcare

GSK to sell off part of its HIV venture ViiV Healthcare The firm can expect a further boost from the recently-launched Triumeq, which gained approval from the US FDA in August and was licensed in the EU in September. ... GSK's CEO Andrew Witty said ViiV had made “very significant progress in both R&D and

ViiV bags US approval for HIV blockbuster-in-waiting

ViiV bags US approval for HIV blockbuster-in-waiting Triumeq combines ViiV's antiretroviral stalwarts lamivudine and abacavir with its brand new integrase inhibitor Tivicay (dolutegravir), which was approved in the US last August and in Europe in January. ... have suggested combination tablets such as

Biosimilar Lantus leads CHMP opinions

Biosimilar Lantus leads CHMP opinions Triumeq – a combination of already-approved treatments Tivicay (dolutegravir) and Kivexa (abacavir/lamivudine) – was recommended to treat HIV infection in adults and adolescents aged 12 years and older.

[ Previous 5 results ] 2 3 4 5 6

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Kendle Healthcare

Company founder Neil Kendle was a pioneer in opinion leader engagement. In 2003, Neil brought together a small, dedicated team...

Latest intelligence

How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....
Cell and gene therapy
Tackling the manufacturing cost and complexity challenges...
2019: CRISPR and therapeutic gene editing comes of age
Can gene-editing deliver safe and effective therapeutics for patients with intractable diseases?...

Infographics